ImmuPharma plc (LON:IMM – Get Free Report) shares fell 31.4% during trading on Tuesday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. 27,337,178 shares changed hands during trading, an increase of 242% from the average session volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Stock Performance
The firm has a fifty day simple moving average of GBX 10.96 and a 200 day simple moving average of GBX 5.84. The company has a market capitalization of £34.63 million, a PE ratio of -7.74 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Upcoming IPO Stock Lockup Period, Explained
- D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
- How to Choose Top Rated Stocks
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- Investing In Preferred Stock vs. Common Stock
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
